CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK.

Favourable outcomes with CPX-351 versus conventional 7 + 3 were demonstrated in the pivotal phase III trial in adults aged 60-75 years with newly diagnosed, highrisk/secondary acute myeloid leukaemia (AML). As a complement to the clinical trial and to address important data gaps, the CPX-351 Real-World Effectiveness and SafeTy (CREST-UK; NCT05169307) study evaluated the use of CPX-351 in routine clinical practice in the UK, in 147 patients with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes. Best response of complete remission or complete remission with incomplete platelet or neutrophil recovery was achieved by 53% of evaluable patients.

Reliability of anthropometric measurements in children with special needs.

Objective: To determine the reliability of anthropometric and body composition measurements in children with special needs.

Design: Observational study.

Setting: Specialist support schools (primary and secondary) in Manchester, UK.

Vitamin D status of gastrostomy-fed children with special needs: a cross-sectional pilot study.

Aim: To assess the vitamin D status of gastrostomy-fed children.

Methods: Vitamin D status was measured in 32 children aged five to 16 years recruited from special schools in Manchester, UK (53° 48 N). All children were receiving a nutritionally complete, commercially prepared enteral feed via gastrostomy, and had been established on this regimen for over 12 months.